PARP Inhibitors in the Treatment of Ovarian Cancer
Introduction Ovarian cancer is a leading cause of cancer mortality globally due to late-stage diagnosis and limited treatment options. PARP inhibitors have shown promise as effective treatments for recurrent and various stages of ovarian cancer. Aim of the Study This study reviews the eff...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2025-02-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/57677 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856500964065280 |
|---|---|
| author | Andrzej Paweł Zuzak Magdalena Cieślik-Porębska Krzysztof Kułak Jagoda Niewiadomska |
| author_facet | Andrzej Paweł Zuzak Magdalena Cieślik-Porębska Krzysztof Kułak Jagoda Niewiadomska |
| author_sort | Andrzej Paweł Zuzak |
| collection | DOAJ |
| description |
Introduction
Ovarian cancer is a leading cause of cancer mortality globally due to late-stage diagnosis and limited treatment options. PARP inhibitors have shown promise as effective treatments for recurrent and various stages of ovarian cancer.
Aim of the Study
This study reviews the efficacy and application of PARP inhibitors in ovarian cancer treatment over the past 15 years, focusing on literature from the PubMed database post-2009 and considering FDA and EMA guidelines.
Review methods
A literature review was conducted using the PubMed database, focusing on studies published after 2009. The review also incorporated recommendations from the FDA and the European Medicines Agency regarding the use of PARP inhibitors in ovarian cancer treatment.
Results
The findings highlight the substantial impact of PARP inhibitors on ovarian cancer treatment, improving PFS and overall outcomes. Olaparib, niraparib, and rucaparib have become integral to ovarian cancer management, offering effective options for patients with BRCA mutations or homologous recombination deficiencies. These inhibitors have been validated in multiple clinical trials, underscoring their robustness and effectiveness. Combination therapies, such as olaparib with bevacizumab, further enhance therapeutic outcomes, showcasing the potential for synergistic effects.
Summary
PARP inhibitors represent a significant advancement in ovarian cancer treatment, offering improved survival outcomes for patients with specific genetic profiles. Their integration into standard care protocols underscores their importance and efficacy, providing valuable therapeutic options in the fight against ovarian cancer.
Key Words: PARP inhibitors, ovarian cancer, ovarian cancer treatment
|
| format | Article |
| id | doaj-art-6834b262f73148389dc07f060751836d |
| institution | Kabale University |
| issn | 2391-8306 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj-art-6834b262f73148389dc07f060751836d2025-02-12T08:17:48ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062025-02-017810.12775/JEHS.2025.78.57677PARP Inhibitors in the Treatment of Ovarian CancerAndrzej Paweł Zuzak0https://orcid.org/0009-0008-6578-1457Magdalena Cieślik-Porębska1https://orcid.org/0009-0002-2226-4317Krzysztof Kułak2https://orcid.org/0000-0001-9059-484XJagoda Niewiadomska 3https://orcid.org/0009-0003-2219-984XDepartment of Gynaecological Oncology and Gynaecology, Student’s Scientific Association at the I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of LublinStudent’s Scientific Association at the I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin Staszica 16 St., 20-081, Lublin, PolandDepartment of Oncological Gynaecology and Gynaecology,, Medical University of Lublin Staszica 16 St., 20-081, Lublin, PolandStudent’s Scientific Association at the I Chair and Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin Staszica 16 St., 20-081, Lublin, Poland Introduction Ovarian cancer is a leading cause of cancer mortality globally due to late-stage diagnosis and limited treatment options. PARP inhibitors have shown promise as effective treatments for recurrent and various stages of ovarian cancer. Aim of the Study This study reviews the efficacy and application of PARP inhibitors in ovarian cancer treatment over the past 15 years, focusing on literature from the PubMed database post-2009 and considering FDA and EMA guidelines. Review methods A literature review was conducted using the PubMed database, focusing on studies published after 2009. The review also incorporated recommendations from the FDA and the European Medicines Agency regarding the use of PARP inhibitors in ovarian cancer treatment. Results The findings highlight the substantial impact of PARP inhibitors on ovarian cancer treatment, improving PFS and overall outcomes. Olaparib, niraparib, and rucaparib have become integral to ovarian cancer management, offering effective options for patients with BRCA mutations or homologous recombination deficiencies. These inhibitors have been validated in multiple clinical trials, underscoring their robustness and effectiveness. Combination therapies, such as olaparib with bevacizumab, further enhance therapeutic outcomes, showcasing the potential for synergistic effects. Summary PARP inhibitors represent a significant advancement in ovarian cancer treatment, offering improved survival outcomes for patients with specific genetic profiles. Their integration into standard care protocols underscores their importance and efficacy, providing valuable therapeutic options in the fight against ovarian cancer. Key Words: PARP inhibitors, ovarian cancer, ovarian cancer treatment https://apcz.umk.pl/JEHS/article/view/57677PARP inhibitorsovarian cancerovarian cancer treatment |
| spellingShingle | Andrzej Paweł Zuzak Magdalena Cieślik-Porębska Krzysztof Kułak Jagoda Niewiadomska PARP Inhibitors in the Treatment of Ovarian Cancer Journal of Education, Health and Sport PARP inhibitors ovarian cancer ovarian cancer treatment |
| title | PARP Inhibitors in the Treatment of Ovarian Cancer |
| title_full | PARP Inhibitors in the Treatment of Ovarian Cancer |
| title_fullStr | PARP Inhibitors in the Treatment of Ovarian Cancer |
| title_full_unstemmed | PARP Inhibitors in the Treatment of Ovarian Cancer |
| title_short | PARP Inhibitors in the Treatment of Ovarian Cancer |
| title_sort | parp inhibitors in the treatment of ovarian cancer |
| topic | PARP inhibitors ovarian cancer ovarian cancer treatment |
| url | https://apcz.umk.pl/JEHS/article/view/57677 |
| work_keys_str_mv | AT andrzejpawełzuzak parpinhibitorsinthetreatmentofovariancancer AT magdalenacieslikporebska parpinhibitorsinthetreatmentofovariancancer AT krzysztofkułak parpinhibitorsinthetreatmentofovariancancer AT jagodaniewiadomska parpinhibitorsinthetreatmentofovariancancer |